Last reviewed · How we verify
Pomalidomide, Cyclophosphamide, Prednisone
At a glance
| Generic name | Pomalidomide, Cyclophosphamide, Prednisone |
|---|---|
| Sponsor | Fondazione EMN Italy Onlus |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas (PHASE1)
- Selinexor, Cyclophosphamide and Prednisone in Myeloma (PHASE2)
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients (PHASE2)
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients (PHASE1, PHASE2)
- Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide (PHASE1, PHASE2)
- Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: